Key facts
- It has raised $62.0M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($62.0M) in Jan 2025.
- Notable investors include Mubadala Investment Company, Bristol-Myers Squibb, Versant Ventures, AbbVie Ventures, Taiho Ventures.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Light Horse Therapeutics
Funding rounds
1 roundsAbout Light Horse Therapeutics
Operator of a small molecule drug discovery company intended to develop new CRISPR-based functional site-dependency maps. The company's platform employs chemical and computational biology tools and precision genome editing methods, enabling researchers to identify functional sites on better-value oncology protein targets for therapeutic intervention.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2020
- Employees
- 39
- Website
- lighthorsetx.com/
- Ownership
- Privately Held (backing)
Light Horse Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Light Horse Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Light Horse Therapeutics in its N-PORT filings yet. We sweep new filings monthly.